Lipoprotein(a) and HIV | Zendy

Byambaa Enkhmaa | Zendy; Erdembileg Anuurad | Zendy; Wei Zhang | Zendy; Chin-Shang Li | Zendy; Robert C. Kaplan | Zendy; Jason Lazar | Zendy; Dan Merenstein | Zendy; Roksana Karim | Zendy; Brad Aouizerat | Zendy; Mardge H. Cohen | Zendy; Kenneth R. Butler | Zendy; Savita Pahwa | Zendy; Igho Ofotokun | Zendy; Adaora A. Adimora | Zendy; Elizabeth T. Golub | Zendy; Lars Berglund | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lipoprotein(a) and HIV

Author(s) -

Byambaa Enkhmaa,

Erdembileg Anuurad,

Wei Zhang,

Chin-Shang Li,

Robert C. Kaplan,

Jason Lazar,

Dan Merenstein,

Roksana Karim,

Brad Aouizerat,

Mardge H. Cohen,

Kenneth R. Butler,

Savita Pahwa,

Igho Ofotokun,

Adaora A. Adimora,

Elizabeth T. Golub,

Lars Berglund

Publication year - 2017

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.117.309137

Subject(s) - human immunodeficiency virus (hiv) , lipoprotein(a) , medicine , lipoprotein , biology , cholesterol , immunology

In the general population, lipoprotein(a) [Lp(a)] has been established as an independent causal risk factor for cardiovascular disease. Lp(a) levels are to a major extent regulated by a size polymorphism in the apolipoprotein(a) [apo(a)] gene. The roles of Lp(a)/apo(a) in human immunodeficiency virus (HIV)-related elevated cardiovascular disease risk remain unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research